NDAORALSOLUTION
Approved
Dec 2024
Lifecycle
Growth
Competitive Pressure
0/100
Data completeness
4/8 — Partial
ONTRALFY (tizanidine hydrochloride) by Biofidelity is alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. Approved for spasticity in adults. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ONTRALFY is an oral solution formulation of tizanidine hydrochloride, an alpha-2-adrenergic receptor agonist approved in December 2024 for spasticity in adults. It reduces spasticity by increasing presynaptic inhibition of motor neurons, with greatest effects on polysynaptic pathways. This is a new branded entry in an established generic category.
Growth16.0 years to LOE
Early-stage growth product with 16+ years of patent protection; team expansion expected as market penetration ramps against established generic competition.
Mechanism of Action
alpha-2-adrenergic receptor agonist and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons.
Indications (1)
Career Relevance
ONTRALFY represents a rare growth-stage branded generic opportunity with 16+ years of market exclusivity and zero linked job openings at present—suggesting either stealth hiring or reliance on contractor/agency models during ramp-up. Professionals joining now will build the commercial franchise from ground zero in a proven therapeutic category, requiring strong market access and physician relationship expertise to overcome incumbent ZANAFLEX inertia.
Worked on ONTRALFY at Biofidelity? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.